Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Metagenomi, Inc. - Common Stock
(NQ:
MGX
)
1.850
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Metagenomi, Inc. - Common Stock
Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights
September 06, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Metagenomi
August 21, 2024
Via
Benzinga
Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
August 19, 2024
Via
Benzinga
MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024
May 14, 2024
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
May 02, 2024
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Thursday's Intraday Session
May 02, 2024
Via
Benzinga
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
May 02, 2024
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet
February 19, 2024
A bumpy start can't detract from this company's strong balance sheet.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.